Targeting apoptosis in cancer therapy
For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
of therapies promoting the effective elimination of cancer cells by apoptosis. This …
MET-dependent solid tumours—molecular diagnosis and targeted therapy
Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma
Comprehensive knowledge of the genomic alterations that underlie cancer is a critical
foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to …
foundation for diagnostics, prognostics, and targeted therapeutics. Systematic efforts to …
Drug development of MET inhibitors: targeting oncogene addiction and expedience
The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and
angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can …
angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can …
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
JG Christensen, J Burrows, R Salgia - Cancer letters, 2005 - Elsevier
Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib,
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non–small cell lung cancer
PC Ma, R Jagadeeswaran, S Jagadeesh… - Cancer research, 2005 - AACR
Non–small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an
attractive potential target for novel therapeutic inhibition in human cancers. We provide …
attractive potential target for novel therapeutic inhibition in human cancers. We provide …
c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions
PC Ma, T Kijima, G Maulik, EA Fox, M Sattler, JD Griffin… - Cancer research, 2003 - AACR
Small cell lung cancer (SCLC) is an aggressive cancer, and most patients present with
cancer already spread beyond the lung. The receptor tyrosine kinase (RTK) c-MET has been …
cancer already spread beyond the lung. The receptor tyrosine kinase (RTK) c-MET has been …
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
DL Shattuck, JK Miller, KL Carraway III, C Sweeney - Cancer research, 2008 - AACR
Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-
free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed …
free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed …
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
SV Sharma, J Settleman - Genes & development, 2007 - genesdev.cshlp.org
In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first
punch setting the stage and the second delivering the knock-out. This analogy can be …
punch setting the stage and the second delivering the knock-out. This analogy can be …
Targeting the c-Met signaling pathway in cancer
B Peruzzi, DP Bottaro - Clinical cancer research, 2006 - AACR
On binding to the cell surface receptor tyrosine kinase (TK) known as c-Met, hepatocyte
growth factor (HGF) stimulates mitogenesis, motogenesis, and morphogenesis in a wide …
growth factor (HGF) stimulates mitogenesis, motogenesis, and morphogenesis in a wide …